Comparison of ddI Versus Zidovudine in HIV-Infected Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To compare the effectiveness and toxicity of didanosine (ddI) and zidovudine (AZT) in
patients with AIDS, advanced AIDS-related complex (ARC), or asymptomatic infection with CD4
counts < 200 cells/mm3.
AZT is effective in reducing mortality in patients with AIDS who receive the drug after the
first episode of Pneumocystis carinii pneumonia (PCP) and in patients with advanced ARC.
However, AZT therapy has been associated with significant toxicities. In addition, the
effectiveness of AZT appears to decrease during the second and third years of therapy. For
these reasons, the development of alternative therapy that would be at least as effective but
less toxic is of great importance. The drug ddI is an antiviral agent that inhibits
replication (reproduction) of HIV with less apparent toxicity than AZT.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)